Literature DB >> 19680801

Fish based preimplantation genetic diagnosis to prevent DiGeorge syndrome.

Shai Shefi1, Gil Raviv, Shlomit Rienstein, Gad Barkai, Ayala Aviram-Goldring, Jacob Levron.   

Abstract

PURPOSE: To report the performance of fluorescence in-situ hybridization in the setting of preimplantation genetic diagnosis in order to diagnose embryos affected by DiGeorge syndrome.
DESIGN: Case report.
SETTING: Academic referral center. PATIENT: A 32 year-old female affected by DiGeorge syndrome. INTERVENTION(S): History and physical examination, karyotyping, amniocentesis, preimplantation genetic diagnosis, fluorescence in-situ hybridization. MAIN OUTCOME MEASURE(S): Avoidance of pregnancy with embryo affected by DiGeorge syndrome. RESULT(S): Termination of pregnancy with an affected embryo followed by fluorescence in-situ hybridization based preimplantation genetic diagnosis and delivery of healthy offspring. CONCLUSION(S): The combination of preimplantation genetic diagnosis with fluorescence in-situ hybridization is recommended to prevent pregnancies with DiGeorge syndrome affected embryos in properly selected patients.

Entities:  

Mesh:

Year:  2009        PMID: 19680801      PMCID: PMC2758949          DOI: 10.1007/s10815-009-9334-6

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  12 in total

1.  Sex and the single cell.

Authors:  Alan Handyside
Journal:  New Sci       Date:  1990-04-21       Impact factor: 0.319

Review 2.  22q11.2 deletion syndrome: DiGeorge, velocardiofacial, and conotruncal anomaly face syndromes.

Authors:  B F Cuneo
Journal:  Curr Opin Pediatr       Date:  2001-10       Impact factor: 2.856

3.  Pre-implantation diagnosis of genetic disease.

Authors:  E Coonen
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1996-08       Impact factor: 2.435

4.  DiGeorge syndrome: part of CATCH 22.

Authors:  D I Wilson; J Burn; P Scambler; J Goodship
Journal:  J Med Genet       Date:  1993-10       Impact factor: 6.318

Review 5.  Velo-cardio-facial syndrome: a review of 120 patients.

Authors:  R Goldberg; B Motzkin; R Marion; P J Scambler; R J Shprintzen
Journal:  Am J Med Genet       Date:  1993-02-01

6.  Velo-cardio-facial syndrome associated with chromosome 22 deletions encompassing the DiGeorge locus.

Authors:  P J Scambler; D Kelly; E Lindsay; R Williamson; R Goldberg; R Shprintzen; D I Wilson; J A Goodship; I E Cross; J Burn
Journal:  Lancet       Date:  1992-05-09       Impact factor: 79.321

7.  A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardio-facial syndrome.

Authors:  R J Shprintzen; R B Goldberg; M L Lewin; E J Sidoti; M D Berkman; R V Argamaso; D Young
Journal:  Cleft Palate J       Date:  1978-01

8.  Genetic counseling for the 22q11.2 deletion.

Authors:  Donna M McDonald-McGinn; Elaine H Zackai
Journal:  Dev Disabil Res Rev       Date:  2008

9.  Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome.

Authors:  Doron Gothelf; Gadi Presburger; Ada H Zohar; Merav Burg; Ariela Nahmani; Moshe Frydman; Mordechai Shohat; Dov Inbar; Ayala Aviram-Goldring; Josepha Yeshaya; Tamar Steinberg; Yehuda Finkelstein; Amos Frisch; Abraham Weizman; Alan Apter
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2004-04-01       Impact factor: 3.568

10.  Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: cast a wide FISHing net!

Authors:  D M McDonald-McGinn; M K Tonnesen; A Laufer-Cahana; B Finucane; D A Driscoll; B S Emanuel; E H Zackai
Journal:  Genet Med       Date:  2001 Jan-Feb       Impact factor: 8.822

View more
  2 in total

Review 1.  Cardiovascular Precision Medicine in the Genomics Era.

Authors:  Alexandra M Dainis; Euan A Ashley
Journal:  JACC Basic Transl Sci       Date:  2018-05-30

Review 2.  Consequences of 22q11.2 Microdeletion on the Genome, Individual and Population Levels.

Authors:  Małgorzata Karbarz
Journal:  Genes (Basel)       Date:  2020-08-22       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.